Identification of biomarker patterns in a biological sample, such as serum or plasma, can dramatically increase the success of almost any drug development program. Myriad RBM’s MAP approach provides investigators with a reliable platform that allows discovery, validation, and clinical use of these patterns in a cost-effective, efficient manner.
Myriad RBM’s Human MAPs represent the most comprehensive menu of quantitative, multiplexed immunoassays commercially available. Our Human MAPs provide insight into multiple pathways to help better understand the underlying biology.
Please click on the following MAPs for a complete list of included analytes.
|Serum or plasma||Other fluids*|
|Human DiscoveryMAP® 250+||750 µL||2.5 mL|
|Human DiscoveryMAP® 175+||500 µL||2 mL|
|Human OncologyMAP®||500 µL||2 mL|
|HumanMAP®||120 µL||650 µL|
|Human CardiovascularMAP®||100 µL||350 µL|
|Human AngiogenesisMAP™||200 µL||500 µL|
|Human InflammationMAP®||100 µL||200 µL|
|Human KidneyMAP®||100 µL||350 µL|
|Human MetabolicMAP®||100 µL||350 µL|
|Human TruCulture® MAP||100 µL||200 µL (TruCulture® Supernatant)|
|Human CytokineMAP A||50 µL||100 µL|
|Human CytokineMAP B||50 µL||100 µL|
|Human IP-10MAP||50 µL**||N/A|
|Human SMA-MAP||100 µL||300 µL|
*Cerebrospinal fluid, urine, tissue culture supernatants, bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.
**Plasma only. Plasma should be collected in BD P700 tubes, specialized vacutainers that are pre-loaded with DPPIV inhibitors, to prevent extra-corporeal cleavage of IP-10
If your volumes are not sufficient, please contact Rules Based Medicine for other options and information.
Myriad RBM is a CLIA certified laboratory that supports GLP studies. All testing is performed to the highest standards of scientific quality in accordance with our standard operating procedures and applicable regulatory requirements.
Please click here to read more about our laboratory’s quality standards and MAP validation process.